Idiopathic anaphylaxis yardstick and biologics for asthma, plus interesting letters on diverse allergy topics
Idiopathic anaphylaxis yardstick and biologics for asthma, plus interesting letters on diverse allergy topics
I hope your winter hasn’t been too harsh so far. The midsouth of the United States is having a milder than usual season, but there is still a great deal of moisture. Such days offer opportunities for a little inside time for reading. I can think of no better reading material than the Annals of Allergy, Asthma & Immunology. I’d like to suggest a few articles for your reading and educational pleasure. An absolute “must read” is the latest idiopathic anaphylaxis yardstick, which is focused on practical recommendations for clinical practice. This series has been very popular among readers, as it is a succinct overview of the specific disease with focused approaches to diagnostic and therapeutic challenges. The choices among approved biologics for asthma are multiple, yet it is still unclear which biologic is best for which patient. The clinical trials that proved the efficacy and safety of these biologics were often similar in their inclusion criteria, study designs, and endpoints. Many of these trials have been reanalyzed post hoc to identify subsets of subjects considered to be so-called “enhanced responders.” This has actually added to the confusion about selecting the appropriate biologic for difficult-to-control asthma patients. This review summarizes and compares trial designs, patient cohorts and study results of the major trials involving these therapies.
I want to emphasize our Letters section of the journal. In this month’s issue there are 14 letters addressing topics as diverse as drug anaphylaxis, environmental influences on manifestations of allergic gastrointestinal disease, and therapeutic responses to biologics in patients with an unusual mast cell-based illness (hereditary alpha tryptasemia). This section is brief, yet power-packed with information that you can read all at once or in snippets that take only a few minutes each.
As we look to the spring allergy season, I hope each of you will continue to support us by reading the articles and offering feedback as to what is (and is not) useful to you in the care of our patients.
Gailen D. Marshall, Jr., MD PhD FACAAI Editor-in-chief
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.